On Friday, Canadian Solar Inc. (NASDAQ:CSIQ)’s shares declined -3.25% to $34.82.
On April 7, Renewable Energy Trust Capital, Inc. (RET Capital) has attaind the 14.1-megawatt DC (MW DC) CityLights solar power plant in Chesterville, Ontario, from Canadian Solar, Inc. (CSIQ). With the close of this deal, RET Capital now owns three solar plants built by Canadian Solar across the province, totaling more than 40 MW DC of generating capacity.
Power from RET Capital’s CityLights plant and its sister solar plants, DiscoveryLight and FotoLight, is being sold to the Independent Electricity System Operator (IESO)—the largest power provider in Ontario—under a 20-year feed-in tariff contract.
“RET Capital is excited to add this high-quality plant and its long-term energy delivery contracts to our growing portfolio of solar assets in the United States and Canada,” said John A. Bohn, Chief Executive Officer and Chairman of RET Capital.
Canadian Solar offered turnkey engineering, procurement, and construction services, and will continue to operate and maintain the plant.
“Canadian Solar has had a long friendship with RET Capital in the renewable energy industry, and the sale of this third plant underscores our successful partnershipwith them,” said Dr. Shawn Qu, Chairman and Chief Executive Officer of Canadian Solar. “We believe in our corporate mission and look forward to contributing to the solar landscape in North America.”
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar module products worldwide. The company operates in two segments, Module and Project. Its products comprise various solar modules that are used in residential, commercial, and industrial solar power generation systems.
StemCells Inc. (NASDAQ:STEM)’s shares dropped -3.41% to $0.91, during the last trading session on Friday.
On April 16, StemCells Inc. declared that it has accomplished transplanting the six patients comprising the first cohort of its Phase II Pathway(R) Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the Company’s proprietary HuCNS-SC(R) (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI).
“We are breaking new ground with this study,” said Stephen Huhn, M.D., FACS, FAAP, vice president, CNS clinical research and CMO at StemCells, Inc. “This is the first controlled study to use neural stem cells with the intent to demonstrate improvement in motor function following spinal cord injury. In this first cohort, we have achieved the highest number of neural stem cells administered into the injured human spinal cord in medical history. We expect to release six month interim data on the first cohort later this year.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.
At the end of Friday’s trade, FXCM Inc. (NYSE:FXCM)‘s shares dipped -3.18% to $2.13.
On April 14, FXCM Inc. declared certain key operating metrics for March 2015 for its retail and institutional foreign exchange business.
Monthly activities comprised of:
March 2015 Retail Trading Metrics
- Retail customer trading volume (1) of $375 billion in March 2015, 40% higher than February 2015 and 29% higher than March 2014. Volume from indirect sources was 36% of total retail volume (1) in the first quarter 2015. Retail customer trading volume (1) for the first quarter 2015 was $1.1 trillion, 20% lower than the fourth quarter 2014, and 17% higher than the first quarter 2014.
- Average retail customer trading volume (1) per day of $17.1 billion in March 2015, 29% higher than February 2015 and 24% higher than March 2014.
- An average of 591,122 retail client trades per day in March 2015, 15% higher than February 2015 and 38% higher than March 2014.
- Tradable accounts (2) of 222,279 as of March 31, 2015, a decrease of 440 accounts, or 0.2% from February 2015, and a raise of 33,016 accounts, or 17%, from March 2014.
March 2015 Institutional Trading Metrics
- Institutional customer trading volume (1) of $248 billion in March 2015, 53% higher than February 2015 and 24% higher than March 2014.
- Average institutional trading volume (1) per day of $11.3 billion in March 2015, 40% higher than February 2015 and 19% higher than March 2014.
- An average of 53,827 institutional client trades per day in March 2015, 72% higher than February 2015 and 43% higher than March 2014.
FXCM Inc., through its auxiliaries, provides online foreign exchange (FX) trading and related services to retail and institutional customers worldwide. The company operates in two segments, Retail Trading and Institutional Trading. It acts as an agent between retail customers and a collection of global banks and financial institutions by making foreign currency markets for customers trading in foreign exchange spot markets.
On Friday, Fairchild Semiconductor International Inc. (NASDAQ:FCS), declared results for the first quarter ended March 29, 2015. Fairchild stated first quarter sales of $355.7 million, up 6 percent from the preceding quarter and 3 percent from the first quarter of 2014.
Fairchild stated first quarter net income of $1.1 million or $0.01 per diluted share contrast to net losses of $42.7 million or $0.36 per diluted share in the preceding quarter and $9.3 million or $0.07 per diluted share in the first quarter of 2014. Gross margin was 30.4 percent contrast to 31.0 percent in the preceding quarter and 30.3 percent in the year-ago quarter.
Fairchild stated first quarter adjusted gross margin of 31.6 percent, down 80 basis points from the preceding quarter and 130 basis points higher than the first quarter of 2014. Adjusted gross margin excludes accelerated depreciation related to factory closures. Adjusted net income was $13.3 million or $0.11 per diluted share, contrast to $11.9 million or $0.10 per diluted share in the preceding quarter and $4.9 million or $0.04 per diluted share in the first quarter of 2014. See the Reconciliation of Net Income (Loss) to Adjusted Net Income exhibit comprised of in this press release for more details on the other adjustment items.
Fairchild Semiconductor International, Inc. designs, develops, manufactures, and markets power analog, power discrete, and non-power semiconductor solutions worldwide. It operates through three segments: Mobile, Computing, Consumer, and Communication (MCCC); Power Conversion, Industrial, and Automotive (PCIA); and Standard Discrete and Standard Linear (SDT).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
